{"id":"cimetra-2","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-15%","effect":"Dizziness"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CimetrA-2 acts by binding to cannabinoid receptors in the body, which can help to reduce inflammation and alleviate symptoms associated with certain medical conditions.","oneSentence":"CimetrA-2 is a synthetic cannabinoid receptor agonist.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:05:54.123Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment-resistant epilepsy"}]},"trialDetails":[{"nctId":"NCT05037162","phase":"PHASE2","title":"Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19","status":"COMPLETED","sponsor":"MGC Pharmaceuticals d.o.o","startDate":"2022-10-11","conditions":"Covid19, Corona Virus Infection","enrollment":240},{"nctId":"NCT04802382","phase":"PHASE3","title":"Clinical Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19","status":"UNKNOWN","sponsor":"MGC Pharmaceuticals d.o.o","startDate":"2021-06-11","conditions":"Corona Virus Infection, Covid19, SARS-CoV Infection","enrollment":252}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CimetrA- 2 drug administration"],"phase":"phase_3","status":"active","brandName":"CimetrA-2","genericName":"CimetrA-2","companyName":"MGC Pharmaceuticals d.o.o","companyId":"mgc-pharmaceuticals-d-o-o","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CimetrA-2 is a synthetic cannabinoid receptor agonist. Used for Treatment-resistant epilepsy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}